



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

Kazutaka Ikeda, et al

:GROUP ART UNIT: 1637

SERIAL NO: 10/073,647

:EXAMINER: STRZELECKA, TERESA E

FOR: METHOD FOR EVALUATING DRUG SENSITIVITY

DECLARATION UNDER 37 C.F.R. SECTION 1.132

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

SIR

I, Kazutaka Ikeda of Department of Molecular Psychiatry of Tokyo Institute of Psychiatry, 2-1-8, Kamikitazawa, Setagaya-ku, Tokyo, who deposes and states that:

1. I am one of the inventors of the invention of the above identified application.

2. I am a graduate of Department of Neuropharmacology and Neuropathology, Brain Research Institute, Niigata University, and awarded the degree of PhD.

3. I have been working as a researcher since 1995, and I am currently head of Department of Molecular Psychiatry of Tokyo Institute of Psychiatry.

4. I have understood the Office Action dated October 17, 2003.

5. The following experiments were conducted by me and collaborators including Professor Ichiro Sora.

The numbers of polymorphisms in an untranslated region of

mRNA of μ -opioid receptor gene of Japanese subjects


To know the numbers of polymorphisms in an untranslated region of mRNA of μ -opioid receptor gene of Japanese subjects, we performed the following experiments.

By phenol extraction process, we obtained genome samples from blood of 44 Japanese subjects. The average age of the 44 subjects was 35.9 ± 1.0 . The Male/Female ratio of the 44 subjects was 3/1.

We amplified DNA fragment of μ -opioid receptor gene by PCR using the obtained genome samples. Comparing the obtained DNA sequences, we found 56 polymorphisms in an untranslated region of mRNA of μ -opioid receptor gene of Japanese subjects.

6. I hereby declare that all statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of application or any patent issuing thereon.

Date: February 18, 2004



Kazutaka Ikeda